Rheumatoid Arthritis (RA)NCT07069088
This Study Aims to Characterize and Compare Patients of Adult-onset RA With Patients of Elderly-onset RA Based on the Clinical Manifestations, Disease Activity, Severity Parameters, and Therapeutic Features
An observational study of Rheumatoid Arthritis (RA), run by Sohag University at 1 site in Egypt.
Trial summary
This study aims to characterize and compare patients of adult-onset RA with patients of elderly-onset RA based on the clinical manifestations, disease activity, severity parameters, and therapeutic features. Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Rheumatoid Arthritis (RA)
- How many people
- 150 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jul 2025to 1 Mar 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Rheumatoid Arthritis patients
Who may be able to join
- 1) Patients fulfill the 2010 American College of Rheumatology/ European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis [7] 2) Age of disease onset above 16 years old. 3) patient is cooperative and can answer questions. 4) Patients who are able and willing to give written informed consent.
Who cannot join
- 1) Other rheumatologic or collagen diseases. 2) Age below 16 years. 3) Active infection 4) Pregnancy 5) Malignancy 6) Uncooperative patients. 7) Patient not able and willing to give written informed consent.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Rheumatology and Rehabilitation department at Sohag University Hospital
Sohag
About this study
Official title: Clinical Characteristics of Elderly-Onset Versus Adult-Onset Rheumatoid Arthritis; a Cross-Sectional Study
This study aims to characterize and compare patients of adult-onset RA with patients of elderly-onset RA based on the clinical manifestations, disease activity, severity parameters, and therapeutic features.
- Conditions
- Rheumatoid Arthritis (RA)
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Adult- onset RA group I (16-40 years) | 16-40 years | |
| Adult- onset RA group II (41-60 years) | 41-60 years | |
| EORA >60 years | >60 years |
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease activity assessment
Disease activity assessment using DAS 28 Quality of life: HAQ (health assessment questionnaire
Measured: from enrollment time to the end of examination and investigation at 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2025
- Study start1 Jul 2025
- Primary completion1 Jan 2026 (estimated)
- Study completion1 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rheumatoid Arthritis (RA)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sara Ahmed Abdelrazik, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07069088
- Sponsor's protocol ID
- Soh-Med--25-6-5MS
- Status last verified
- Jun 2025
- First submitted
- 30 Jun 2025
- Last updated
- 16 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All patients will be subjected to the following: 1. Full medical history from the patients, including Demographic data (Age, Sex, Marital status, Occupation, Residence), duration of disease, Comorbidities, and the treatments that patients receive. 2. Full clinical examination and assessment including: 1. General examination and Complete rheumatological examination. 2. Application of American College of Rheumatology/ European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis, on all RA patients. 3. Laboratory investigations: (Blood sample will be collected into 5ml tubes containing Ethylenediaminetetraacetic acid (EDTA) ). * complete blood count (CBC) (done on fully automatic BC 21S hematology analyzer). * erythrocyte sedimentation rate (ESR). * C- reactive protein (CRP) (using Enzyme-linked immunosorbent assay (ELISA)). * rheumatoid factor (RF) (using ELISA). * anti-cyclic citrullinated peptide antibody (ACCP Ab) (using ELISA). 4. Disease activity assessm